Association of PCSK9 inhibitors with bone disease: A comprehensive drug-target Mendelian randomization study

Yuyang Zhang[1,2,3], Xiaohui Wang[1,2,3], Hao Yang[1], and Dingjun Hao*[1,2,3]

[1] Translational Medicine Center, Hong Hui Hospital, Xi'an Jiaotong University, Xi'an, 710054, China

[2] Department of Spine Surgery, Hong Hui Hospital, Xi'an Jiaotong University, Xi'an, 710054, China

[3] Shaanxi Key Laboratory of Spine Bionic Treatment, Xi'an, Shaanxi, 710054, China

* Correspondence:

Dageng Huang

huangdageng@mail.xjtu.edu.cn

Dingjun Hao

haodingjun@mail.xjtu.edu.cn

Abstract

Background:

Emerging research indicates that PCSK9 inhibitors, which originally developed for lowering LDL cholesterol, may positively impact bone skeletal system. By potentially enhancing bone density and strength, PCSK9 inhibitors offer a promising new avenue in bone disease management, signaling a significant shift in therapeutic strategies.

Methods: This study employed a comprehensive approach involving the extraction of single-nucleotide polymorphisms (SNPs) from genome-wide association studies (GWAS), followed by

rigorous quality checks. PCSK9 instrumental variables were utilized to evaluate the effect of

cholesterol-lowering drugs on osteoporosis, osteoarthritis, and rheumatoid arthritis. Cross-Phenotype

Association Analysis (CPASSOC) and colocalization analysis were conducted to identify

overlapping genetic sites

Results: Our analysis did not reveal a significant causal relationship between lower BMD and the

predicted risk of FCHL. However, there was an observed association between an increased genetic

risk of FCHL and reduced BMD, particularly in younger individuals (TB-BMD (age 15-30): OR =

0.922, 95% CI: 0.844-0.993, P = 0.032). PCSK9 inhibitors were found to increase BMD while

reducing the risk of FCHL. Notably, rs998584 in the VEGFA gene emerged as a shared locus in both

CPASSOC and colocalization analyses, with high expression in Adipo-CAR cells in the bone

marrow.

Conclusions: This study's cross-trait analysis uncovers a shared genetic basis between FCHL and

BMD, elucidating the causal relationship between genetic predisposition to FCHL and the likelihood

of reduced BMD. Our findings contribute to a more nuanced understanding of the genetic factors

influencing bone health in European populations and highlight potential therapeutic targets for

improving BMD in individuals with FCHL.

Keywords: Bone mineral density, Familial combined hyperlipidemia, Mendelian randomization, CPASSOC, Coloc

1 Introduction

Osteoporosis (OP), a prevalent skeletal disorder, is characterized by weakened bones and an

increased risk of fractures(1). It is typically diagnosed through assessments of Bone Mineral Density

(BMD), a key indicator of bone strength and health(2). Despite its clinical importance, the factors

contributing to variations in BMD, and consequently to the risk of OP, are complex and

multifaceted(3). Among these, the relationship between lipid metabolism, specifically

hyperlipidemia, and BMD has garnered considerable interest in the medical community(4).

While some studies have suggested a correlation between hyperlipidemia and alterations in BMD(5,

6, 7), the nature and direction of this association remain subjects of debate in the scientific literature.

Inconsistent findings across epidemiological studies have left gaps in our understanding of how lipid

profiles might influence bone health. This ambiguity extends to the effects of lipid-lowering agents,

such as PCSK9 inhibitors, on BMD. PCSK9 inhibitors, known for their role in managing cholesterol

levels(8, 9) may have implications for bone health(10), yet their impact on BMD is not clearly

understood.

A critical aspect to consider in this context is the distinct nature of Familial Combined

Hyperlipidemia (FCHL). FCHL is characterized by a more complex and severe lipid profile

abnormality, often involving a combination of high cholesterol, elevated triglycerides, and low HDL-

C levels(11). This condition is not only more severe but also has a strong genetic component(12),

making it distinct from more common forms of hyperlipidemia which might be primarily lifestyle-

induced or less severe.

In light of these uncertainties, our study adopted a genetic approach to probe the potential

connections between FCHL and bone health. By extracting and analyzing single-nucleotide

polymorphisms (SNPs) from comprehensive genome-wide association studies (GWAS), we aimed to

explore the genetic underpinnings that might link FCHL – a common but complex form of

hyperlipidemia – with variations in BMD. We employed a bidirectional Mendelian Randomization

(MR) analysis(13) to assess the susceptibility to OP in relation to FCHL, considering BMD

variations across different body regions and age groups. Furthermore, a bidirectional MR analysis

was conducted to delve deeper into the causal dynamics between FCHL and BMD. As a widely used

cholesterol lower drug, we employ the instrument variables of PCSK9 inhibitors to evaluate its

benefit on BMD.

Our research also includes analytical techniques combining cross-phenotype association analysis

(CPASSOC) and colocalization analysis. These methods enabled us to pinpoint overlapping genetic

sites that might influence both FCHL and BMD, which were further explored using single-cell RNA

(scRNA) sequencing data to localize their expression in bone marrow cell clusters.

Through this comprehensive approach, our study sought not only to clarify the relationship between

lipid profiles and bone health but also to identify potential genetic markers and therapeutic targets

that could improve clinical outcomes for individuals with FCHL, thereby contributing to a more

nuanced understanding of bone health determinants.

2   Materials and Methods

Data Acquisition and Processing

The genetic markers for FCHL exposure were sourced from the UK Biobank. The outcomes

considered in this research pertained to BMD variation by specific skeletal site and age. Our

foundational dataset incorporated GWAS summary outcomes for BMD: eBMD (N = 265,627) from

MRC-IEU and TB-BMD (N = 56,284), LS-BMD (N = 28,498), FN-BMD (N = 32,735), and FA-

BMD (N = 8,143) from GEFOS(14). For age-specific BMD categorizations, we used the DXA-

detected TB-BMD metrics and divided them into another five age brackets: 0–15, 15–30, 30–45, 45–

60, and above 60. (15). In a complementary approach, BMD genetic instruments were harnessed,

designating FCHL as the outcome, guided by the Consensus criteria (N = 39,961 cases; 309,261

controls) derived from UK Biobank(16). Table 1 offers an overview of the data sources used and

their respective participant demographics. GWAS summary data for FCHL and BMD were sourced

from the GWAS CatLog. The majority of participansts hailed from European backgrounds. Given the

study's dependence on existing GWAS summary datasets, there was no need for institutional board

approval, though consent was acquired from all contributors.

Genetic instrument selection for PCSK9 inhibitors

The summary data for LDL cholesterol (LDL-C) was sourced from GWAS summary statistics

encompassing 173,082 individuals(17). By identifying instrumental variables targeting PCSK9 to

lower LDL-C, we aimed to mimic the effects of PCSK9 inhibitors(18). To circumvent linkage

disequilibrium issues, we established a linkage disequilibrium threshold ($r^2 \leq 0.3$) and excluded

SNPs that exhibited strong LD with each other. Following this process, 8 significant PCSK9 SNPs

were retained, deemed appropriate as instrumental variables.

Selection of genetic instrumental variants

To derive the most relevant and robust SNPs as genetic instrumental variables (IVs) of the FCHL

data, we adhered to a rigorous selection process: We began by targeting SNPs that exhibited genome-

wide significance for FCHL, characterized by default parameters. A subsequent clumping process

was instituted, governed by criteria (window size = 10,000 kb, $R^2 > 0.001$), to confirm the absence of

linkage disequilibrium (LD) amongst the chosen SNPs. SNPs that were not detected during the R

calculation process within the outcome GWAS were subsequently omitted from our selection. We

further streamlined our selection by discarding SNPs showcasing ambiguity. Leveraging the

capabilities of the PhenoScanner R package(19), SNPs strongly associated with confounders such as

'Ever smoked'(20), 'Type II diabetes'(21), and 'Alcohol intake frequency'(22) were streamlined.

MR analysis

The overarching objective of our Mendelian Randomization (MR) examination was to elucidate the

bidirectional causal interplay between FCHL and BMD, as well as PCSK9 inhibitors on BMD. Our

primary modus operandi was the inverse variance weighted (IVW) technique(23). In a quest for

heightened analytical rigor, we also engaged the MR-Egger regression and median-based estimator

techniques(24). Situations with discernible horizontal pleiotropy saw the deployment of the MR-

PRESSO outlier test(25). Furthermore, our analyses leveraged both IVW and MR Egger regression

to probe horizontal pleiotropic SNP effects, with Cochran's Q-test being instrumental(26) in

heterogeneity quantifications.

Cross-trait meta-analysis

Single-nucleotide polymorphisms (SNPs) were extracted from GWAS summary data, and we

ensured rigorous quality checks. This integration is pivotal for detecting evidence of variants

associated with multiple traits across different studies while controlling for population structure and

relatedness(27). PLINK's "clumping" function to obtain independent loci (parameters: –clump-p1

5e-8 –clump-p2 1e-5 –clump-r2 0.2 –clump-kb 500). SHet calculated by CPASSOC was chosen as

the threshold of significance due to its robustness to heterogeneous effects on the trait. In our

analysis, the pairwise SHet was employed to integrate FCHL association with summary statistics for

BMD traits. We demarcated significant Single Nucleotide Polymorphisms (SNPs) as variants with a

p-value in CPASSOC of less than 5×10^{-8}. To obtain a further functional annotation of the SNPs

identified by CPASSOC, the Ensembl Variant Effect Predictor (VEP)(28) was employed.

Coloc analysis

To address linkage disequilibrium bias in our Mendelian Randomization analyses, we conducted

colocalization analysis using the coloc v5.2.3 R package. We sourced comprehensive GWAS

summary statistics for each disease and risk factor from the IEU OpenGWAS project. For each

protein-phenotype pair, we set a $\pm$ 100 kb window around each instrumental variable (IV) and

r2=0.3. We used a high colocalization threshold (PP.H4_final > 80%) to indicate strong associations.

When dealing with a single causal variant, the average PP.H4 from the coloc.abf output was

calculated for all IVs. In cases with multiple causal variants, we used the highest PP.H4 from

multiple credible sets as provided by the coloc.susie output, ensuring a more robust and bias-

minimized analysis.

scRNA sequencing data analysis

To delve deeper into the cellular localization of VEGFA expression within the bone marrow, we

utilized single-cell RNA sequencing data, sourced from the GEO database under the accession

number GSE122467. Our approach to analyzing this data was methodologically aligned with the

procedures detailed in the original publication associated with this dataset (29). For the processing

and analysis of the single-cell RNA sequencing data, we employed the Seurat v4.3.0 R package(30).

Robust analysis

We employed the Cochran Q-test metrics to measure heterogeneities. To evaluate possible horizontal

pleiotropic impacts of the SNPs, we used IVW (random effect) and MR-Egger regression techniques.

Moreover, we executed a "leave-one-out" sensitivity assessment to pinpoint any SNPs that might

have a pronounced influence. In this approach, we sequentially removed each SNP to ascertain if it

drove the observed association.

Statistical Analysis

Bonferroni correction (corrected p = 0.05/X*Y, where X represents the number of exposures and Y represents the number of outcomes) was used to adjust for multiple testing in this MR. All statistical analyses employed the Two-Sample MR (version 0.5.7) (31) and CPASSOC R packages in R software (version 4.1.3).

3   Results

3.1   PCSK9 inhibitor significantly increases BMD

PCSK9 inhibitors, known for their effectiveness in hyperlipidemia treatment, particularly in Familial Combined Hyperlipidemia (FCHL), were examined for their influence on Bone Mineral Density (BMD). Using the ieu-a300 dataset, we identified eight significant SNPs associated with PCSK9 inhibitors as instrumental variables (Supplementary Table 5).

Our Mendelian Randomization (MR) analysis revealed that PCSK9 inhibitors significantly reduced the risk of FCHL (Odds Ratio: 0.3311, 95% CI: 0.286-0.383, P.adj = 3.2e-50; Figure 4A, Supplementary Table 6). Further, we found a positive association of PCSK9 inhibitors with increased Lumbar Spine-BMD (LS-BMD; OR=1.157, 95% CI: 0.963 -1.330, p.adj=0.0442) and Total Body-BMD in the 15-30 age group (OR=1.391, 95% CI: 1.022-1.638, p.adj=0.0357), as shown in Figure 4 B, C and detailed in Supplementary Table 7.

These findings suggest a role of PCSK9 inhibitors in reducing FCHL risk and enhancing BMD, highlighting their potential broader application in clinical practice for bone health management.

3.2   Pcsk9 oa

In our pursuit to uncover individual SNPs that influence both Familial Combined Hyperlipidemia

(FCHL) and Bone Mineral Density (BMD), we conducted a detailed pairwise Cross-Phenotype

Association Analysis (CPASSOC). This analysis, as detailed in Table 2 and Supplementary Table 8,

led to the identification of 10 shared independent loci between FCHL and BMD. These loci include

rs4665972 (SNX17), rs2489623 (RSPO3), rs2737263 (TRPS1), rs556107 (RP4-781K5.7),

rs114165349 (ARID1A), rs4810479 (PLTP), rs998584 (VEGFA), rs342437 (AFF1), rs12740374

(CELSR2), and rs62086884 (C17orf58). Notably, all these SNPs satisfied the stringent SHet criterion

of CPASSOC ($< \square 5 \times 10^{-8}$). The functional annotations of these SNPs, as provided by the Ensembl

Variant Effect Predictor, are comprehensively detailed in Supplementary Table 9. Among these

identified SNPs, rs12740374 was previously established as being associated with FCHL at a genome-

wide significance level. In contrast, the majority of the SNPs (6 out of 10) were predominantly linked

to BMD traits.

To further validate our findings, we conducted a coloc analysis for FCHL and BMD traits. This

analysis yielded a surprising result: rs998584 in the VEGFA gene, already identified in the

CPASSOC analysis, was also pinpointed as a colocalized SNP. This intriguing overlap is depicted in

Figure 5 and elaborated in Supplementary Table 10. This dual identification of rs998584 in both

CPASSOC and coloc analyses underscores its potential significance in the shared genetic pathways

influencing both FCHL and BMD.

3.3   Pcsk9 inhibitor RA

Building on our previous analysis that highlighted the VEGFA gene as a crucial shared locus for

Familial Combined Hyperlipidemia (FCHL) and Bone Mineral Density (BMD), we ventured to

pinpoint the specific expression of VEGFA in the bone marrow's heterogeneous environment. For

this purpose, we utilized publicly available single-cell RNA sequencing data.

Our analysis, visualized through a dot plot in Figure 6, revealed that the primary cell type expressing

VEGFA in bone marrow is the Adipo-CAR cells. Adipo-CAR, an abbreviation for CXCL12-

abundant-reticular cells, are a specialized type of stromal cells. A defining characteristic of Adipo-

CAR cells is their high expression of the leptin receptor (LEPR), a protein that binds leptin. Leptin is

a hormone crucial for regulating energy balance and metabolism. This finding is particularly

intriguing given the involvement of Adipo-CAR cells in the bone marrow's microenvironment and

their potential influence on bone physiology.

Drawing on these insights, we propose a hypothesis wherein hyperlipidemia could stimulate Adipo-

CAR cells to produce an increased level of VEGFA. This upregulation of VEGFA might

subsequently impact BMD by altering the dynamic equilibrium between bone formation and

resorption. Such a mechanism could provide a cellular and molecular basis for the observed

association between FCHL and variations in BMD, offering a novel perspective on how metabolic

disturbances can influence bone health.

3.4   Robustness

The MR-Egger regression method was utilized to investigate the potential existence of horizontal

pleiotropy among the SNPs and the result. Our results did not identify any evidence of such

pleiotropy (all $p > 0.05$) (Supplementary Tables 4). Similarly, the funnel plots did not display any

apparent horizontal pleiotropy for the evaluated outcomes (Refer to Supplementary Figure 2).

Additionally, the leave-one-out sensitivity charts revealed that no individual SNP significantly

impacted the causal association, emphasizing the strength of our conclusions (See Supplementary

Figures 2-3). In summary, our data indicates that the neutral connection between a genetic

predisposition to FCHL and a likelihood of decreased BMD was not predominantly influenced by

any particular SNP.

4   Discussion

The findings of our study offer novel insights into the complex interplay between lipid metabolism

and bone health, particularly in the context of Familial Combined Hyperlipidemia (FCHL) and its

relationship with Bone Mineral Density (BMD). While our analysis did not establish a significant

causal link between lower BMD and an increased risk of FCHL, it did highlight an interesting

association between genetic predisposition to FCHL and reduced BMD, especially in younger

individuals. This observation aligns partially with previous studies suggesting a negative correlation

between hyperlipidemia and BMD but extends the understanding by pinpointing specific age groups

where this association is more pronounced.

The role of PCSK9 inhibitors in this relationship adds another layer of complexity. Our findings

suggest that PCSK9 inhibitors, beyond their primary role in managing cholesterol levels, might

positively influence BMD. This dual effect, both reducing the risk of FCHL and potentially

increasing BMD, could have significant implications for clinical practice, especially in managing

patients with hyperlipidemia who are also at risk for OP.

One of the most striking results of our study is the identification of the rs998584 SNP in the VEGFA

gene as a shared locus between FCHL and BMD, highly expressed in Adipo-CAR cells in the bone

marrow. VEGFA is known to participate in growth of vascular endothelial. Surprisingly, plasma

VEGFA levels were suggested to contribute to the lipoprotein variation(32). In addition, it has

previously been shown to be an important pro-osteogenic cue of endochondral bone ossification(33).

We believe that our analysis would provide new insights for investigating the common molecular

mechanisms of BMD and FCHL. This finding not only strengthens the genetic link between lipid

metabolism and bone health but also suggests a potential cellular mechanism for this association.

Adipo-CAR cells, known for their role in supporting bone marrow structure and function, could be a

key site where hyperlipidemia influences bone health.

Given the heterogeneity in existing epidemiological data regarding the relationship between lipid

profiles and BMD, our study contributes to a more nuanced understanding of this association. The

use of Mendelian Randomization allows for a more rigorous examination of causality that might not

be as discernible in observational studies. However, it is essential to acknowledge the limitations

inherent in this approach, such as the potential for pleiotropy and the assumption that the genetic

variants used as instrumental variables are only associated with the exposure of interest.

In conclusion, our study underscores the need for a holistic approach in managing patients with

hyperlipidemia, considering not only the cardiovascular implications but also the potential impact on

bone health. The identification of specific genetic loci shared between FCHL and BMD opens up

new avenues for research and potential therapeutic intervention. Future studies could explore the

mechanisms by which PCSK9 inhibitors and other lipid-modifying treatments might influence bone

metabolism and whether these treatments could be leveraged to improve bone health in patients with

hyperlipidemia.

5   Conclusion

This study demonstrates that susceptibility to familial combined hyperlipidemia (FCHL) is causally

associated with lower bone mineral density (BMD), particularly in younger populations.

Furthermore, PCSK9 inhibitors significantly reduce the risk of FCHL while concurrently aiding in

the prevention of bone mineral density loss. Additionally, VEGFA, notably expressed in Adipo-CAR

cells, emerges as a pivotal link between FCHL and BMD, suggesting a shared molecular pathway

influencing both conditions.

6   Abbreviation

MR: Mendelian Randomization

IVs: Instrumental variables

FCHL: Familial combined hyperlipidemia

BMD: Bone mineral density

TB-BMD: Total body-bone mineral density

LS-BMD: Lumbar spine bone mineral density

FN-BMD: Femoral neck bone mineral density

FA-BMD: Forearm bone mineral density

eBMD: Heel bone mineral density

IVW: Inverse variance weighted

SNPs: single nucleotide polymorphisms

OR: Odds ratio

7   Declarations

7.1   Ethics approval and consent to participate.

Not applicable.

7.2 Consent for publication

Not applicable.

7.3 Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

7.4 Availability of data and material

The datasets analyzed for this study can be found in the IEU OpenGWAS https://gwas.mrcieu.ac.uk/datasets/ and the GEO database https://www.ncbi.nlm.nih.gov/geo.

7.5 Funding

This work was supported by Special Support Project for High-level Talents of Shaanxi Province (2020), Shaanxi Provincial Key Research and Development Project (2020GXLH-Y-027), Scientific Research Project of Xi 'an Health Commission (2020qn16) and National Natural Science Foundation of China (NSFC, Grant code: 81830077).

7.6 Authors' contributions

Conceived the idea: DH and YZ; Manuscript draft: YZ; Downloaded and collected data: KS, XW; Analyzed the data: YZ, DL; Prepared figures: KS, DL, XW; Redressed the manuscript: YH, DH; Reviewed the manuscript: All authors. This study was completed with teamwork. Each author had made corresponding contribution to the study. All authors contributed to the article and approved the submitted version.

7.7 Acknowledgments

We unfeignedly thank MD. Xue Chen (Central Hospital, China National Petroleum Corporation, Chengdu, China) for generously sharing his experiences.

8 Reference

1.   Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. The Lancet.
2011;377(9773):1276-87.

2.   Haseltine KN, Chukir T, Smith PJ, Jacob JT, Bilezikian JP, Farooki A. Bone Mineral
Density: Clinical Relevance and Quantitative Assessment. J Nucl Med. 2021;62(4):446-54.

3.   Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364-76.

4.   Hernandez JL, Olmos JM, Ramos C, Martinez J, de Juan J, Valero C, et al. Serum lipids and
bone metabolism in Spanish men: the Camargo cohort study. Endocr J. 2010;57(1):51-60.

5.   Brownbill RA, Ilich JZ. Lipid profile and bone paradox: higher serum lipids are associated
with higher bone mineral density in postmenopausal women. J Womens Health (Larchmt).
2006;15(3):261-70.

6.   Xie R, Huang X, Liu Q, Liu M. Positive association between high-density lipoprotein
cholesterol and bone mineral density in U.S. adults: the NHANES 2011-2018. J Orthop Surg Res.
2022;17(1):92.

7.   Kim YH, Nam GE, Cho KH, Choi YS, Kim SM, Han BD, et al. Low bone mineral density is
associated with dyslipidemia in South Korean men: the 2008-2010 Korean National Health and
Nutrition Examination Survey. Endocr J. 2013;60(10):1179-89.

8.   Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in
PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154-6.

9.   Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol.
2019;16(3):155-65.

10.   Xie W, Li J, Du H, Xia J. Causal relationship between PCSK9 inhibitor and autoimmune
diseases: a drug target Mendelian randomization study. Arthritis Res Ther. 2023;25(1):148.

11.   Bello-Chavolla OY, Kuri-Garcia A, Rios-Rios M, Vargas-Vazquez A, Cortes-Arroyo JE,
Tapia-Gonzalez G, et al. Familial Combined Hyperlipidemia: Current Knowledge, Perspectives, and
Controversies. Rev Invest Clin. 2018;70(5):224-36.

12.   Brouwers MC, van Greevenbroek MM, Stehouwer CD, de Graaf J, Stalenhoef AF. The
genetics of familial combined hyperlipidaemia. Nat Rev Endocrinol. 2012;8(6):352-62.

13.   Zheng J, Baird D, Borges MC, Bowden J, Hemani G, Haycock P, et al. Recent Developments
in Mendelian Randomization Studies. Curr Epidemiol Rep. 2017;4(4):330-45.

14.   Zheng HF, Forgetta V, Hsu YH, Estrada K, Rosello-Diez A, Leo PJ, et al. Whole-genome
sequencing identifies EN1 as a determinant of bone density and fracture. Nature.
2015;526(7571):112-7.

15.   Medina-Gomez C, Kemp JP, Trajanoska K, Luan J, Chesi A, Ahluwalia TS, et al. Life-
Course Genome-wide Association Study Meta-analysis of Total Body BMD and Assessment of Age-
Specific Effects. Am J Hum Genet. 2018;102(1):88-102.

16.   Trinder M, Vikulova D, Pimstone S, Mancini GBJ, Brunham LR. Polygenic architecture and
cardiovascular risk of familial combined hyperlipidemia. Atherosclerosis. 2022;340:35-43.

17.   Elsworth B, Lyon M, Alexander T, Liu Y, Matthews P, Hallett J, et al. The MRC IEU
OpenGWAS data infrastructure. 2020.

18.   Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et
al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of

coronary heart disease: A multivariable Mendelian randomisation analysis. PLoS Med.
2020;17(3):e1003062.

19.   Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, et al. PhenoScanner
V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics.
2019;35(22):4851-3.

20.   Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral
density. Calcif Tissue Int. 2001;68(5):259-70.

21.   Lin HH, Hsu HY, Tsai MC, Hsu LY, Chien KL, Yeh TL. Association between type 2
diabetes and osteoporosis risk: A representative cohort study in Taiwan. PLoS One.
2021;16(7):e0254451.

22.   Godos J, Giampieri F, Chisari E, Micek A, Paladino N, Forbes-Hernandez TY, et al. Alcohol
Consumption, Bone Mineral Density, and Risk of Osteoporotic Fractures: A Dose-Response Meta-
Analysis. Int J Environ Res Public Health. 2022;19(3).

23.   Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple
genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658-65.

24.   Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:
effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-25.

25.   Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in
causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat
Genet. 2018;50(5):693-8.

26.   Bowden J, Del Greco MF, Minelli C, Zhao Q, Lawlor DA, Sheehan NA, et al. Improving the
accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME
assumption. Int J Epidemiol. 2019;48(3):728-42.

27.   Li X, Zhu X. Cross-Phenotype Association Analysis Using Summary Statistics from GWAS.
Methods Mol Biol. 2017;1666:455-67.

28.   Cunningham F, Allen JE, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, et al. Ensembl
2022. Nucleic Acids Res. 2022;50(D1):D988-D95.

29.   Baccin C, Al-Sabah J, Velten L, Helbling PM, Grunschlager F, Hernandez-Malmierca P, et
al. Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone
marrow niche organization. Nat Cell Biol. 2020;22(1):38-48.

30.   Hao Y, Hao S, Andersen-Nissen E, Mauck WM, 3rd, Zheng S, Butler A, et al. Integrated
analysis of multimodal single-cell data. Cell. 2021;184(13):3573-87 e29.

31.   Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base
platform supports systematic causal inference across the human phenome. Elife. 2018;7.

32.   Stathopoulou MG, Bonnefond A, Ndiaye NC, Azimi-Nezhad M, El Shamieh S, Saleh A, et
al. A common variant highly associated with plasma VEGFA levels also contributes to the variation
of both LDL-C and HDL-C. J Lipid Res. 2013;54(2):535-41.

33.   Hu K, Olsen BR. The roles of vascular endothelial growth factor in bone repair and
regeneration. Bone. 2016;91:30-8.

9   Figure legends

Figure 1. A step-by-step illustration of the study design and workflow

Figure 2. A: Causal impact of FCHL on BMD by site; B: Causal impact of FCHL on BMD by age.

Use IVW to draw the Forest plot of the causal relationship between FCHL and BMD based on

anatomical location. OR: odds ratio; IVW: inverse variance weighting; CI: confidence interval.

Figure 3. A: Causal impact of BMD by site on FCHL; B: Causal impact of BMD by age on FCHL.

Use IVW to draw the Forest plot of the causal relationship between FCHL and BMD based on age.

OR: odds ratio; IVW: inverse variance weighting; CI: confidence interval.

Figure 4. A: Causal impact of PCSK9 inhibitor IVs on FCHL; B: Causal impact of PCSK9 inhibitor

IVs on BMD by body site; C: Causal impact of PCSK9 inhibitor IVs on BMD by age. Use IVW to

draw the Forest plot of the causal relationship between BMD based on anatomical location and

FCHL. OR: odds ratio; IVW: inverse variance weighting; CI: confidence interval.

Figure 5 Locus map of rs998584, VEGFA identified by coloc.

Figure 6 A: UMAP of public scRNA data; B: Distribution of VEGFA expression on public scRNA

data; C: Dotplot of VEGFA expression among different cell clusters.

A

Outcome	Method	nsnp	OR(95% CI)	p.adj
TB-BMD	MR Egger	70	0.977(0.943 to 1.010)	0.16643969
	Weighted median	70	0.972(0.942 to 1.001)	0.05873343
	Inverse variance weighted	**70**	**0.974(0.953 to 0.994)**	**0.01270492**
	Weighted mode	70	0.973(0.946 to 0.999)	0.04575423
FN-BMD	MR Egger	40	0.973(0.912 to 1.032)	0.20390974
	Weighted median	40	0.994(0.944 to 1.044)	0.44858468
	Inverse variance weighted	**40**	**0.998(0.965 to 1.032)**	**0.50462033**
	Weighted mode	40	0.983(0.925 to 1.040)	0.30630683
FA-BMD	MR Egger	45	0.988(0.890 to 1.087)	0.51007842
	Weighted median	45	1.033(0.944 to 1.120)	0.29567699
	Inverse variance weighted	**45**	**1.018(0.960 to 1.076)**	**0.34310276**
	Weighted mode	45	1.023(0.926 to 1.121)	0.40300680
eBMD	MR Egger	49	1.005(0.981 to 1.028)	0.57270570
	Weighted median	49	0.991(0.975 to 1.007)	0.23196402
	Inverse variance weighted	**49**	**0.996(0.983 to 1.009)**	**0.43416161**
	Weighted mode	49	0.996(0.975 to 1.018)	0.58466040
LS-BMD	MR Egger	41	0.997(0.927 to 1.066)	0.50974522
	Weighted median	41	0.962(0.907 to 1.016)	0.09081743
	Inverse variance weighted	**41**	**0.983(0.945 to 1.022)**	**0.21587654**
	Weighted mode	41	0.965(0.897 to 1.032)	0.17080192

0.5 1 1.5
← Lower BMD   Higher BMD →

B

Outcome	Method	nsnp	OR(95% CI)	p.adj
TB-BMD (age 0-15)	MR Egger	65	0.914(0.822 to 0.997)	0.04173605
	Weighted median	65	0.939(0.868 to 1.008)	0.07226971
	Inverse variance weighted	**65**	**0.961(0.911 to 1.011)**	**0.10982701**
	Weighted mode	65	0.910(0.827 to 0.985)	0.02052168
TB-BMD (age 15-30)	MR Egger	64	0.879(0.739 to 1.003)	0.05313916
	Weighted median	64	0.892(0.778 to 0.994)	0.03399366
	Inverse variance weighted	**64**	**0.922(0.844 to 0.993)**	**0.02863685**
	Weighted mode	64	0.898(0.783 to 1.002)	0.05305911
TB-BMD (age 30-45)	MR Egger	68	1.008(0.933 to 1.082)	0.79093380
	Weighted median	68	0.990(0.920 to 1.059)	0.72304403
	Inverse variance weighted	**68**	**0.984(0.935 to 1.032)**	**0.47040643**
	Weighted mode	68	0.997(0.935 to 1.059)	0.87614696
TB-BMD (age 45-60)	MR Egger	71	0.988(0.939 to 1.036)	0.60341824
	Weighted median	71	0.979(0.932 to 1.025)	0.36023379
	Inverse variance weighted	**71**	**0.979(0.947 to 1.011)**	**0.18811798**
	Weighted mode	71	0.979(0.935 to 1.023)	0.33499895
TB-BMD (age over 60)	MR Egger	70	0.978(0.925 to 1.030)	0.39218634
	Weighted median	70	0.979(0.933 to 1.024)	0.35029665
	Inverse variance weighted	**70**	**0.999(0.966 to 1.033)**	**0.94170137**
	Weighted mode	70	0.979(0.936 to 1.022)	0.33147755

0.5 1 1.5
← Lower BMD   Higher BMD →

A

Exposure	Method		nsnp	OR(95% CI)	p.adj
TB−BMD	MR Egger		80	0.997(0.862 to 1.132)	0.96666830
	Weighted median		80	0.985(0.926 to 1.044)	0.61223951
	Inverse variance weighted		**80**	**0.985(0.934 to 1.037)**	**0.57413300**
	Weighted mode		80	0.964(0.881 to 1.046)	0.38930792
FN−BMD	MR Egger		20	1.085(0.623 to 1.540)	0.73155594
	Weighted median		20	1.008(0.918 to 1.099)	0.85786661
	Inverse variance weighted		**20**	**1.060(0.970 to 1.146)**	**0.19542495**
	Weighted mode		20	0.977(0.808 to 1.145)	0.78623709
FA−BMD	MR Egger		3	0.786(0.543 to 0.976)	0.27419696
	Weighted median		3	1.020(0.942 to 1.099)	0.61494460
	Inverse variance weighted		**3**	**1.015(0.887 to 1.142)**	**0.82408751**
	Weighted mode		3	0.948(0.861 to 1.032)	0.34439620
eBMD	MR Egger		337	0.984(0.916 to 1.052)	0.64890278
	Weighted median		337	0.980(0.926 to 1.034)	0.46334528
	Inverse variance weighted		**337**	**1.029(0.992 to 1.066)**	**0.12471955**
	Weighted mode		337	0.934(0.861 to 1.003)	0.05990873
LS−BMD	MR Egger		21	0.979(0.726 to 1.232)	0.87410477
	Weighted median		21	1.020(0.938 to 1.101)	0.63898838
	Inverse variance weighted		**21**	**1.045(0.980 to 1.108)**	**0.17859030**
	Weighted mode		21	1.015(0.874 to 1.157)	0.83534766

B

Exposure	Method		nsnp	OR(95% CI)	p.adj
TB−BMD (age 0−15)	MR Egger		8	0.768(0.424 to 1.048)	0.14795968
	Weighted median		8	0.990(0.907 to 1.073)	0.81395502
	Inverse variance weighted		**8**	**0.996(0.933 to 1.060)**	**0.90588292**
	Weighted mode		8	1.000(0.882 to 1.117)	0.99524273
TB−BMD (age 30−45)	MR Egger		9	0.932(0.666 to 1.194)	0.61735225
	Weighted median		9	0.953(0.885 to 1.019)	0.15718806
	Inverse variance weighted		**9**	**0.961(0.909 to 1.012)**	**0.13589880**
	Weighted mode		9	0.945(0.855 to 1.033)	0.25025098
TB−BMD (age 45−60)	MR Egger		20	0.847(0.650 to 1.018)	0.09418108
	Weighted median		20	0.994(0.929 to 1.059)	0.85160744
	Inverse variance weighted		**20**	**1.011(0.955 to 1.067)**	**0.70557349**
	Weighted mode		20	0.992(0.899 to 1.086)	0.87491884
TB−BMD (age over 60)	MR Egger		19	0.948(0.697 to 1.196)	0.68179940
	Weighted median		19	1.017(0.945 to 1.088)	0.64395590
	Inverse variance weighted		**19**	**1.052(0.989 to 1.113)**	**0.10732771**
	Weighted mode		19	0.992(0.884 to 1.100)	0.89219575

A

Outcome	Method		nsnp	OR(95% CI)	p.adj
FCHL	MR Egger		8	0.277(0.230 to 0.333)	9.660432e−06
	Weighted median		8	0.318(0.274 to 0.368)	1.792810e−52
	Inverse variance weighted		**8**	**0.331(0.286 to 0.383)**	**3.235587e−50**
	Weighted mode		8	0.293(0.252 to 0.340)	8.932427e−07

0.2　　　　1

← Lower Risk of FCHL　Higher Risk of FCHL →

B

Outcome	Method		nsnp	OR(95% CI)	p.adj
TB−BMD	MR Egger		8	0.998(0.880 to 1.116)	0.97386007
	Weighted median		8	1.010(0.925 to 1.094)	0.82240245
	Inverse variance weighted		**8**	**0.995(0.924 to 1.066)**	**0.89579775**
	Weighted mode		8	1.023(0.915 to 1.130)	0.69037377
FN−BMD	MR Egger		3	1.077(0.456 to 1.692)	0.32002922
	Weighted median		3	1.016(0.840 to 1.191)	0.32299897
	Inverse variance weighted		**3**	**1.010(0.852 to 1.167)**	**0.33818871**
	Weighted mode		3	1.089(0.887 to 1.283)	0.18309426
FA−BMD	MR Egger		5	0.963(0.708 to 1.216)	0.49240345
	Weighted median		5	0.935(0.745 to 1.121)	0.30261068
	Inverse variance weighted		**5**	**0.915(0.739 to 1.084)**	**0.19521950**
	Weighted mode		5	0.957(0.754 to 1.157)	0.43027732
eBMD	MR Egger		8	1.024(0.983 to 1.066)	0.29839417
	Weighted median		8	1.017(0.981 to 1.053)	0.36371687
	Inverse variance weighted		**8**	**1.004(0.976 to 1.032)**	**0.77685467**
	Weighted mode		8	1.022(0.983 to 1.059)	0.31119563
LS−BMD	MR Egger		3	1.049(0.267 to 1.828)	0.34672970
	Weighted median		3	1.149(0.943 to 1.335)	0.06160699
	Inverse variance weighted		**3**	**1.157(0.963 to 1.330)**	**0.04418783**
	Weighted mode		3	1.147(0.897 to 1.377)	0.14240915

0.5　　　　1　　　　1.5

← Lower BMD　Higher BMD →

C

Outcome	Method		nsnp	OR(95% CI)	p.adj
TB−BMD (age 0−15)	MR Egger		8	1.033(0.756 to 1.309)	0.82391161
	Weighted median		8	1.067(0.854 to 1.276)	0.54778079
	Inverse variance weighted		**8**	**1.096(0.925 to 1.258)**	**0.28135780**
	Weighted mode		8	1.041(0.808 to 1.273)	0.74346220
TB−BMD (age 15−30)	MR Egger		8	1.404(0.781 to 1.899)	0.27883566
	Weighted median		8	1.243(0.821 to 1.614)	0.28256659
	Inverse variance weighted		**8**	**1.391(1.022 to 1.638)**	**0.03565528**
	Weighted mode		8	1.205(0.752 to 1.621)	0.42785311
TB−BMD (age 30−45)	MR Egger		8	1.045(0.743 to 1.344)	0.78558697
	Weighted median		8	1.060(0.828 to 1.288)	0.61950886
	Inverse variance weighted		**8**	**1.090(0.903 to 1.269)**	**0.35620613**
	Weighted mode		8	1.058(0.830 to 1.284)	0.63830109
TB−BMD (age 45−60)	MR Egger		8	0.791(0.539 to 0.993)	0.08991522
	Weighted median		8	0.851(0.674 to 1.004)	0.05592673
	Inverse variance weighted		**8**	**0.873(0.729 to 1.000)**	**0.05017874**
	Weighted mode		8	0.839(0.651 to 0.999)	0.08958605
TB−BMD (age over 60)	MR Egger		8	1.046(0.852 to 1.238)	0.66229735
	Weighted median		8	1.020(0.870 to 1.170)	0.79547035
	Inverse variance weighted		**8**	**0.948(0.828 to 1.065)**	**0.37441648**
	Weighted mode		8	1.019(0.854 to 1.183)	0.83218251

0.5　　　　1　　　　1.5

← Lower BMD　Higher BMD →

A

B

Vegfa

C